B. Braun Medical has received the US Food and Drug Administration (FDA) approval for the use of Piperacillin and Tazobactam in its Duplex drug delivery system.
Piperacillin and Tazobactam are indicated for treating intra-abdominal infections, nosocomial pneumonia, skin infections, female pelvic infections, and community-acquired pneumonia.
The antibacterial and a beta-lactamase inhibitor combination in the Duplex system offers a ready-to-activate, two-compartment container that simplifies the administration process.
With the FDA approval, the company can commence a full commercial launch of the product, a significant development in the field of injectable antibiotics in the US.
B. Braun Medical marketing senior director Jeremy Greene said: “We are excited to introduce Piperacillin and Tazobactam in our innovative Duplex Drug Delivery System, designed to save time, labour, and space, and reduce waste.
“Enhancing efficiency for nurses and pharmacists aligns with our commitment to providers and the patients they serve. And, the Duplex Container is not made with DEHP or PVC, further protecting patients and the environment.”
The Duplex Drug Delivery System separates pre-measured medication and diluent until administration, reducing the overall process time by nearly four minutes per dose.
The system offers substantial labour time savings compared to the Baxter Mini-Bag Plus Container System and traditional compounding methods
Designed to minimise contamination risks and medication errors, it provides healthcare professionals with an effective way to administer the antibiotic combination.
The Duplex system features a closed-system design that maintains drug potency and ensures the diluent cannot be delivered without the drug.
Building on fewer process steps, the system reduces medication errors by 54% compared to traditional compounding methods.
It requires no thawing and can be stored at room temperature or in automated dispensing cabinets.
Piperacillin and Tazobactam in the Duplex Drug Delivery System marks the second Duplex Drug launch this year, following Cefazolin.
B. Braun plans to introduce more injectable drugs in the US in the coming years to expand its portfolio and address patient needs.
